OOIR: Observatory of International Research

Papers

(The median citation count of JAMA Oncology is 1. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)

Article	Citations
Analysis of Outcomes With Addition of Immunotherapy to Chemoradiation Therapy for Non–Small Cell Lung Cancer—Reply	1139
Coding Error in Study Evaluating Eligibility of US Black Women Under USPSTF Lung Cancer Screening Guidelines	373
Reducing the Risks of Nuclear War—The Role of Health Professionals	324
JAMA Network Call for Papers on Health and the 2024 US Election	319
Active Surveillance for Low-risk Papillary Thyroid Carcinoma—Reply	289
JAMA Oncology Peer Reviewers in 2022	278
Metformin—A Thought-provoking Addition to Anticancer Therapies	262
Error in Funding/Support	253
Lower Back Pain in a Patient With Sarcoma	249
Tissue-Based PD-L1 Expression Is the Strongest Predictor of Overall Survival Benefit From ICI in Advanced Gastroesophageal Cancer—Reply	231
Prone Whole-Breast Radiotherapy—Better Than Supine?	229
Errors in Byline and Affiliations	223
Errors in Byline	222
Evidence Base on the Potential Carcinogenicity of Radiofrequency Radiation	214
Interpretation of the Efficacy of Multidisciplinary Geriatric Assessment Intervention on Chemotherapy-Related Toxic Effects in Older Adults With Cancer—Reply	213
Insights Into Immune-Mediated Disease and Cancer Risk—Delivering on the Promise of UK Biobank Big Data	197
Considerations in Narrowing the Breast Cancer Mortality Gap Between Black and White Women	183
JAMA Oncology	179
A Radiation Oncologist’s Experience With Medical Aid in Dying	175
JAMA Oncology	174
JAMA Oncology Peer Reviewers in 2020	166
A Partnership to Advance Care of Patients With Acute Promyelocytic Leukemia	164
Error in Results and Table 1	164
Nivolumab + Ipilimumab as Immunotherapeutic Boost in Metastatic Urothelial Carcinoma	162
Assessment of Response to a Third Dose of the SARS-CoV-2 BNT162b2 mRNA Vaccine in Patients With Solid Tumors Undergoing Active Treatment	160

Methodology Concerns Regarding Claims Data Studies in Transgender Health—Reply	158
High-risk Medulloblastoma—Balancing the High Stakes of Molecular Profiling to Enhance Treatment Responsivity	154
On Diction	152
Outcomes Associated With Thiotepa-Based Conditioning in Patients With Primary Central Nervous System Lymphoma After Autologous Hematopoietic Cell Transplant	147
Carfilzomib, Lenalidomide, and Dexamethasone Followed by Lenalidomide Maintenance for Prevention of Symptomatic Multiple Myeloma in Patients With High-risk Smoldering Myeloma	135
Local Immunoradiotherapy in Patients With Metastatic Soft-Tissue Sarcoma	135
Tumor Mutational Burden in Metastatic Castration-Resistant Prostate Cancer and Response to Checkpoint Inhibition	135
Allogeneic Hematopoietic Cell Transplantation vs Standard Consolidation Chemotherapy in Patients With Intermediate-Risk Acute Myeloid Leukemia	133
Intensity-Modulated Reirradiation Therapy With Nivolumab in Recurrent or Second Primary Head and Neck Squamous Cell Carcinoma	128
Vaccinia (Smallpox) for the Treatment of Ovarian Cancer—Turning an Old Foe Into a Friend?	124
Assessment of a Contralateral Esophagus–Sparing Technique in Locally Advanced Lung Cancer Treated With High-Dose Chemoradiation	123
Forging a Path for Metformin Use in Inoperable Locally Advanced Non–Small Cell Lung Cancer	122
To Treat or Not to Treat Men With Low-risk or Intermediate-risk Prostate Cancer—Weighing the Evidence	121
Association of Adjuvant Immunotherapy Duration With Chronic Immune-Related Adverse Events	120
JAMA Oncology	113
Errors in Title, Abstract, Methods, and Visual Abstract	109
Association of Antineoplastic Therapy With Decreased SARS-CoV-2 Infection Rates in Patients With Cancer	105
Is Pertuzumab Plus Trastuzumab Without Chemotherapy a Reasonable Treatment for ERBB2-Positive Metastatic Breast Cancer?—Reply	105
Mortality and Hospitalization Risks in Patients With Cancer and the SARS-CoV-2 Omicron Variant	104
Association of Radiation and Procarbazine Dose With Risk of Colorectal Cancer Among Survivors of Hodgkin Lymphoma	102
Error in a Supplement	101
Unlocking the Potential of Anti-TIGIT Therapy—Between Promise and Challenges	101
More on Waterpipe Tobacco Smoking and Cancer Mortality Content —Reply	100
Concerns Regarding the Utility of High-Risk Pancreatic Cancer Surveillance—Reply	100
Concerns Regarding the Utility of High-Risk Pancreatic Cancer Surveillance	98
Circulating Tumor DNA as Measurable Residual Disease in Aggressive B-Cell Lymphoma	97
FOLFOX/FOLFIRI–Bevacizumab for Unresectable Colorectal Liver Metastases	97
JAMA Oncology	96
Biomarker Analysis of Vistusertib Plus Paclitaxel Regimen—Reply	96
Stargazers	95
Risk of Death Due to Pregnancy-Associated Cancers—More Questions Than Answers	93
Biomarker Analysis of Vistusertib Plus Paclitaxel Regimen	90
PSMA PET in Prostate Cancer—A Biomarker or a Surrogate End Point?—Reply	89
Ending One’s Life Is Not Always a Sign of Psychopathology—Reply	89
Hypofractionated Radiotherapy for Locally Advanced Non–Small Cell Lung Cancer—Does Size Matter?—Reply	87
Errors in Data and Language	87
Quantifying the Long-term Survival Benefit of Pembrolizumab for Patients With Advanced Gastric Cancer	87
What Is the Optimal Treatment for Vulnerable Older Women With Ovarian Cancer?	87
Stereotactic Ablative Body Radiotherapy for Metastases Needs Better Evidence	83
Randomized Clinical Trials in the Era of Precision Oncology—The Role of End Points, Industry Funding, and Medical Writing Integrity	82
Error in Visual Abstract	80
Is Pertuzumab Plus Trastuzumab Without Chemotherapy a Reasonable Treatment for ERBB2-Positive Metastatic Breast Cancer?	80
Considerations in Meta-Analysis of Immunotherapy for Advanced Cancers Other Than Melanoma	80
Information Blocking and Oncology	80
Errors in Reported Primary and Secondary Outcomes and Table Numbers in a Trial of Radiotherapy for Pain Relief in Patients With Bone Metastases	78
Error in Article Title	78
Is 2045 Optimistic?—Concerns Regarding Rising Vaccine Hesitancy	77
Caution With Routine Use of Daratumumab for Newly Diagnosed High-Risk Multiple Myeloma	76
Evaluating Eligibility of US Black Women Under USPSTF Lung Cancer Screening Guidelines	76
Induction Chemotherapy for Advanced Nasopharyngeal Carcinoma—Is This the New Standard of Care?	74

Misinterpretation of Surgeons’ Statements on Cancer Removal—The Adverse Effects of “We Got It All”	74
Risk, Racial Disparity, and Outcomes Among Patients With Cancer and COVID-19 Infection—Reply	74
Deciphering Genomic Risk in Prostate Cancer—Ready for Prime Time	74
Radiotherapy to Enhance Chimeric Antigen Receptor T-Cell Therapeutic Efficacy in Solid Tumors	73
Clinical Value of Molecular Targets and FDA-Approved Genome-Targeted Cancer Therapies	71
Reporting the Analytical Method Is Essential to Assessing Studies in Which Biomarkers Are a Major Study Objective	71
Prescription Drug Provisions in the Inflation Reduction Act	70
Painful Eruptions in a Patient With Cholangiocarcinoma Treated With Fibroblast Growth Factor Receptor Inhibitor	68
Capecitabine Maintenance in Metastatic Nasopharyngeal Carcinoma	67
Neoadjuvant Endocrine Therapy in Clinical Practice	66
Data Errors in the Results	66
Contemporary Trends in Reviewing Test Results Through the Electronic Patient Portal Among Patients With Cancer	66
Assessment of Hospitalizations and Emergency Department Visits After Chimeric Antigen Receptor T-Cell Therapy Among Commercially Insured Patients	66
A Musical Ode	65
Nontumor Cells in Tumor Samples Bias Expression-Based Models	65
Errors in Key Points and Abstract	64
Out-of-Pocket Costs and Outpatient Visits Among Patients With Cancer in High-Deductible Health Plans	64
Error in Text	64
Outcomes in Patients With Postchemotherapy Residual Nonretroperitoneal Disease in Nonseminomatous Germ Cell Tumors	62
Malignant Pericardial Effusion, or Fluid Around the Heart Due to Cancer	62
Immunotherapy in Prepatients—Preventing or Promoting a Malignant Transformation?	62
JAMA Oncology	61
Omission of Critical Information From Clinical Trial Reports—What to Do About Uninterpretable Results	60
Active Cellular Immunotherapy in the Desert of Advanced Prostate Cancer	60
Leaning Into Uncertainty and Discomfort With Hope	60
Home	60
AIO INTEGA Provides Further Support for Immunotherapy in Patients With Advanced ERBB2-Positive Gastroesophageal Adenocarcinoma	60
Keeping the Heartbeat Off-Target in Cancer Therapy	60
Analysis of Quality-of-Life Outcomes by Drug Class in Cancer Clinical Trials—Reply	59
Comparison of Therapy in Advanced Hepatocellular Carcinoma Based on Clear Definition and Accurate Subgroup Data	59
Caution Regarding Assessment of Toxic Effects and Survival in Treatment De-escalation With Radiotherapy vs Transoral Surgery for Human Papillomavirus–Associated Oropharyngeal Cancer	59
Differences in Thickness-Specific Incidence and Factors Associated With Cutaneous Melanoma in the US From 2010 to 2018	59
High-risk Human Papillomavirus Testing for Cervical Cancer Screening—Reply	59
Association of SARS-CoV-2 Antibody Level With Risk of Infection or Hospitalization—Reply	59
Magnetic Resonance Imaging in Prostate Cancer Screening	58
The Multidisciplinary Cancer Conference	58
Adjuvant Therapy for Pancreatic Adenocarcinoma—Leaving No Rock Unturned	57
Assessment of Severe Maternal Morbidity and Mortality in Pregnancies Complicated by Cancer in the US	57
A Critical Need to Examine the Lack of Access to Healthy Quality Foods and Its Association With Cancer Mortality—A Clarion Call for Multilevel Research and Interventions	57
The 2021 US Preventive Services Task Force Recommendation on Lung Cancer Screening	57
Preserving Fertility in Women With Cancer	57
Long-Term Prospective Outcomes of Intensity Modulated Radiotherapy for Locally Advanced Lung Cancer	56
Utility of Liver Biopsy in Diagnosis and Management of High-grade Immune Checkpoint Inhibitor Hepatitis in Patients With Cancer	56
Valid Analysis of Brain-Specific Progression-Free Survival	56
Performance of Tumor Surveillance for Children With Cancer Predisposition	56
Long-term Effect of Machine Learning–Triggered Behavioral Nudges on Serious Illness Conversations and End-of-Life Outcomes Among Patients With Cancer	56
Piercing the Fog	56
Hyperthermic Intraperitoneal Chemotherapy for Ovarian and Colorectal Cancer	56
Redefining Attribution From Patient to Health System—How the Notion of “Mistrust” Places Blame on Black Patients—Reply	55
Concerns Remain Regarding the Association of Sitting Time and Physical Activity With Cancer Survivorship	55
Diagnosis and Management of Tropomyosin Receptor Kinase Fusion-Positive Thyroid Carcinomas	55
Analysis of Serious Adverse Event Reporting for Patients Enrolled in Cancer Clinical Trials During the COVID-19 Pandemic	55
Effect of Second-generation vs Third-generation Chemotherapy Regimens With Thoracic Radiotherapy on Unresectable Stage III Non–Small-Cell Lung Cancer	55
JAMA Oncology	54
Against All Odds	54
Error in Co–First Author Designation	54
Evaluation of the Durability of the Immune Humoral Response to COVID-19 Vaccines in Patients With Cancer Undergoing Treatment or Who Received a Stem Cell Transplant	53
Research During Wartime—Ethical Challenges Faced by Oncology Researchers in Ukraine	52
The Global Economic Cost of Cancer—Estimating It Is Just the First Step!	51
Inferential Challenges for Real-world Evidence in the Era of Routinely Collected Health Data	51
Errors in Table	51
External Control Arms and Data Analysis Methods in Nonrandomized Trial of Patients With Glioblastoma	51
Error in Affiliations	51
Aiming for the Cure in ERBB2-Positive Metastatic Breast Cancer—Should We Go “All In”?	50
Firearm Safety for Patients Diagnosed With Cancer—A Role in Suicide Prevention	50
Assessment and Prognostic Value of Inflammatory Biomarkers in Patients With Colon Cancer	50
Treatment Options for Relapsed and Refractory Multiple Myeloma	49
Incidence of Cutaneous Adverse Events With Phosphoinositide 3-Kinase Inhibitors as Adjuvant Therapy in Patients With Cancer	49
Association of Modifiable Risk Factors With Early Discontinuation of Adjuvant Endocrine Therapy	49
Comment on the Burden of Infection-Attributable Cancers in the US	48
Nonverbal	48
JAMA Oncology Peer Reviewers in 2023	48
JAMA Oncology—The Year in Review, 2023	48
Endometrial Cancer Classification and Management in the Molecular Subtyping Era	47
Integrating Community Health Workers Into Care for Patients With Advanced Stages of Cancer—Fragility Index Analysis—Reply	47
Moving the Needle on Equity in Prostate Cancer	47
Neoadjuvant Nivolumab Plus Chemotherapy Followed By Response-Adaptive Therapy for HPV⁺ Oropharyngeal Cancer	46
FDG PET Scans in Cancer Care	46
JAMA Oncology—The Year in Review, 2024	45
Early in the Morning	45

Molecular Testing for the World Health Organization Classification of Central Nervous System Tumors	45
Cost of Drug Wastage From Dose Modification and Discontinuation of Oral Anticancer Drugs	44
Overcoming Barriers to Make Patient-Reported Outcome Collection the Standard of Care in Oncology	44
Obstacles to Biosimilar Acceptance and Uptake in Oncology	43
Local Immunoradiotherapy in Patients With Metastatic Soft-Tissue Sarcoma—Reply	43
Cardiovascular Risk in Prostate Cancer—A Call to Action?	42
Long-Term Engagement of Patients With Advanced Cancer	42
Results of the TARGET-TP Randomized Clinical Trial	42
Watch and Wait for Near-Complete Responders—A Word of Caution	42
Results of the TARGET-TP Randomized Clinical Trial—Reply	42
Triplet Therapy in Metastatic Hormone-Sensitive Prostate Cancer—Calling Out the “Double Standard”	41
Impact of Common Vitamin D–Binding Protein Isoforms on Supplemental Vitamin D₃ and/or Calcium Effects on Colorectal Adenoma Recurrence Risk	41
Coffee Consumption and Colorectal Cancer Prognosis—Reply	41
Cardiovascular Safety Communications After US Food and Drug Administration Approval of Contemporary Cancer Therapies	41
Gefitinib vs Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in EGFR-Variant Lung Cancer—Long-Term Results of a Randomized Clinical Trial	41
Measurable Residual Disease and Clinical Outcomes in Chronic Lymphocytic Leukemia	40
Postoperative Management of Prostate Cancer—Optimizing Prostate Cancer Care	40
Waterpipe Tobacco Smoking and Risk of Cancer Mortality	40
Error in Abstract	40
Change in email address	39
A Lived Experience of Breast Cancer as a Scholar of Intersectionality	39
Advancing Genomic Cancer Medicine in Rural and Underserved States	39
Contralateral Breast Cancer Remains a Complex Biologic Conundrum	39
Changes in Opioid Prescriptions and Potential Misuse and Substance Use Disorders Among Childhood Cancer Survivors Following the 2016 Opioid Prescribing Guideline	39
Sexual Rehabilitation Needs of Gay and Bisexual Men With Cancer	39
Systemic Anticancer Therapy and Overall Survival in Patients With Very Advanced Solid Tumors	38
Three-Year Follow-up of Neoadjuvant Chemotherapy With or Without Anthracyclines in the Presence of DualERBB2Blockade in Patients WithERBB2-Positive Breast Cancer	38
Validation of a 22-Gene Genomic Classifier in Patients With Recurrent Prostate Cancer	38
Association of Screening Lower Endoscopy With Colorectal Cancer Incidence and Mortality in Adults Older Than 75 Years	38
Adjuvant Chemotherapy for Stage I Pancreatic Ductal Adenocarcinoma—Is It Based on Evidence or Clinical Wisdom?	37
JAMA Oncology	37
Error in Abstract and Methods	37
Promoting Inclusion of Members of Racial and Ethnic Minority Groups in Cancer Drug Development	37
Crossing Over	37
Addressing the Need for Diversity in Scalp Cooling Trials	37
Radiation Myelitis Risk After Hypofractionated Spine Stereotactic Body Radiation Therapy	36
Risk of Pancreatic Cancer Among Individuals With Pathogenic Variants in the ATM Gene	36
Neoadjuvant Exercise Therapy in Patients With Prostate Cancer—Reply	36
Efficacy, Safety, and Population Pharmacokinetics of MW032 Compared With Denosumab for Solid Tumor–Related Bone Metastases	36
Diversity Trends by Sex and Underrepresented in Medicine Status Among US Radiation and Medical Oncology Faculty Over 5 Decades	36
Rapid Advances in Resectable Non–Small Cell Lung Cancer	35
Adolescents and Young Adults With Cancer	35
Evaluation of Clinical Outcomes of Icotinib in Patients With Clinically Diagnosed Advanced Lung Cancer With EGFR-Sensitizing Variants Assessed by Circulating Tumor DNA Testing	35
Aiming at a Tailored Cure for ERBB2-Positive Metastatic Breast Cancer	35
Perioperative Immune Checkpoint Inhibition in Early-Stage Non–Small Cell Lung Cancer	35
Association Between Overall Survival and the Tendency for Cancer Programs to Administer Neoadjuvant Chemotherapy for Patients With Advanced Ovarian Cancer	35
Radiation-Associated Secondary Cancer in Patients With Breast Cancer Harboring TP53 Germline Variants	34
JAMA Oncology	34
Time-Dependent COVID-19 Mortality in Patients With Cancer	34
Stereotactic Body Radiotherapy for Medically Inoperable Early-Stage Non–Small Cell Lung Cancer	34
Ensuring Safety and Consistency in Artificial Intelligence Chatbot Responses—Reply	34
Prognostic and Predictive Value of Immune-Related Gene Expression Signatures vs Tumor-Infiltrating Lymphocytes in Early-Stage ERBB2/HER2-Positive Breast Cancer	33
Short-term Health Insurance Plans Come Up Short for Patients With Cancer	33
Audit of Data Sharing by Pharmaceutical Companies for Anticancer Medicines Approved by the US Food and Drug Administration	33
Long-term Mortality in Individuals Diagnosed With Cancer During Pregnancy or Postpartum	33
Veliparib Plus Temozolomide for MGMT-Methylated Glioblastoma	33
Has the Current Oncology Value Paradigm Forgotten Patients’ Time?	33
Sotorasib’s Accelerated Approval	33
Human Leukocyte Antigen Class I Antigen-Processing Machinery Upregulation by Anticancer Therapies in the Era of Checkpoint Inhibitors	32
Identification of Immune Checkpoint Inhibitor–Induced Diabetes	32
Efficacy of Treatment With Armodafinil for Cancer-Related Fatigue in Patients With High-grade Glioma	32
Association of Smoking Initiation and Cessation Across the Life Course and Cancer Mortality	32
Treatment With Etirinotecan Pegol for Patients With Metastatic Breast Cancer and Brain Metastases	32
Association of Salpingectomy With Delayed Oophorectomy Versus Salpingo-oophorectomy With Quality of Life in BRCA1/2 Pathogenic Variant Carriers	32
Long-Term Adverse Effects and Complications After Prostate Cancer Treatment	32
Applying a Life Course Biological Age Framework to Improving the Care of Individuals With Adult Cancers	31
Evaluation of Substantial Reduction in Elective Radiotherapy Dose and Field in Patients With Human Papillomavirus–Associated Oropharyngeal Carcinoma Treated With Definitive Chemoradiotherapy	31
Transplant-Free Approach in Relapsed Hodgkin Lymphoma in Children, Adolescents, and Young Adults	31
Inclusion and Reporting of Transgender and Nonbinary Persons in Clinical Trials and Tumor Registries—The Time Is Now	31
Federal Transportation Regulations Limit Access to Clinical Trials and Oncology Care	31
Association Between Neighborhood Socioeconomic Inequality and Cervical Cancer Incidence Rates in New York City	31
Bilateral Oophorectomy and All-Cause Mortality in Women With BRCA1 and BRCA2 Sequence Variations	31
Implications of Selection Bias Due to Delayed Study Entry in Clinical Genomic Studies	30
Pembrolizumab Added to Ifosfamide, Carboplatin, and Etoposide Chemotherapy for Relapsed or Refractory Classic Hodgkin Lymphoma	30
Relapse Rates and Disease-Specific Mortality Following Procedures for Fertility Preservation at Time of Breast Cancer Diagnosis	30
Association of Inflammatory Biomarkers With Survival Among Patients With Stage III Colon Cancer	30
Clinical Activity and Safety of Cabozantinib for Brain Metastases in Patients With Renal Cell Carcinoma	30
Association of Sinoatrial Node Radiation Dose With Atrial Fibrillation and Mortality in Patients With Lung Cancer	30
Atezolizumab and Platinum Plus Pemetrexed With or Without Bevacizumab for Metastatic Nonsquamous Non–Small Cell Lung Cancer	29
The Burden of Lung Cancer in Women Compared With Men in the US	29
The Implications of the Supreme Court Decision to Overturn Roe v Wade for Women With Pregnancy-Associated Cancers	29
Allogeneic CD19/CD22 CAR T-Cell Therapy for B-Cell Acute Lymphoblastic Leukemia	29
Risk of Syndrome-Associated Cancers Among First-Degree Relatives of Patients With Pancreatic Ductal Adenocarcinoma With Pathogenic or Likely Pathogenic Germline Variants	29
Clinicopathologic Characteristics and Prognosis of ERBB2-Low Breast Cancer Among Patients in the National Cancer Database	28
Trends in Late Mortality and Life Expectancy After Allogeneic Blood or Marrow Transplantation Over 4 Decades	28
Deaths Due to COVID-19 in Patients With Cancer During Different Waves of the Pandemic in the US	28
Second Primary Breast Cancer in Young Breast Cancer Survivors	28
Sentinel Node Biopsy for Early Breast Cancer—A SOUND for De-escalation	28
Association of Wildfire Exposure While Recovering From Lung Cancer Surgery With Overall Survival	28
The Inclusion of Women in Global Oncology Drug Trials Over the Past 20 Years	27
Umbilical Cord–Derived Mesenchymal Stromal Cells For Prevention of Chronic Graft-vs-Host Disease—Reply	27
Estimation of Cancer Deaths Averted From Prevention, Screening, and Treatment Efforts, 1975-2020	27
Efficacy of Reduced-Intensity Chemotherapy With Oxaliplatin and Capecitabine on Quality of Life and Cancer Control Among Older and Frail Patients With Advanced Gastroesophageal Cancer	27
The Role of Temozolomide in Patients With Newly Diagnosed Wild-Type IDH, Unmethylated MGMTp Glioblastoma During the COVID-19 Pandemic	27
Atezolizumab Before and After Chemoradiation for Unresectable Stage III Non–Small Cell Lung Cancer	27